No per-user seats. No per-report surprises. One predictable annual rate for your entire drug safety team — sized to your case volume.
Based on real PV industry benchmarks. Adjust the inputs to match your program.
| Feature | Starter | Growth | Scale | Enterprise |
|---|---|---|---|---|
| Annual price | $36,000 | $72,000 | $120,000 | Custom |
| AE case capacity | 500/yr | 2,000/yr | 5,000/yr | Unlimited |
| AI auto-triage + MedDRASuggested PT, SOC, LLT coding | ✓ | ✓ | ✓ | ✓ |
| Reporter intake portal | ✓ | ✓ | ✓ | ✓ |
| 21 CFR Part 11 audit trail | ✓ | ✓ | ✓ | ✓ |
| Unlimited users | ✓ | ✓ | ✓ | ✓ |
| E2B XML export | +$3,600/yr | ✓ | ✓ | ✓ |
| MedWatch direct submission | — | ✓ | ✓ | ✓ |
| Regulatory timeline alerts15-day / 7-day tracking | — | ✓ | ✓ | ✓ |
| EMA EudraVigilance | — | — | ✓ | ✓ |
| Validation docs (IQ/OQ/PQ) | — | — | ✓ | ✓ |
| Dedicated CSM | — | — | ✓ | ✓ |
| SSO / SAML | — | — | ✓ | ✓ |
| Custom integrations | — | — | — | ✓ |
| Support SLA | 24-hr | 4-hr | 1-hr | Custom |
A case is counted when a reporter submission is formally entered into the system — whether spontaneous, clinical trial, or literature-derived. Duplicates merged into a single case count as one.
You'll receive an alert at 80% and 95% of your limit. If you exceed it, you have a 30-day grace period before we contact you about upgrading. We never cut off access mid-month.
Yes. All plans include a complete audit trail, electronic signature support, and access controls that support Part 11 compliance. Scale and Enterprise plans include formal IQ/OQ validation documentation.
Absolutely. Upgrades are prorated and take effect immediately. Your data, configurations, and case history carry over seamlessly.
Beta clients receive 40% off their first year, locked renewal pricing for year two, white-glove onboarding, and direct access to the product team to shape the roadmap.
Yes. A Business Associate Agreement is available on Growth, Scale, and Enterprise plans. AE Connect is built on HIPAA-compliant cloud infrastructure with encryption at rest and in transit.